Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group - PubMed
Clinical Trial
. 1998 Dec;16(12):3744-51.
doi: 10.1200/JCO.1998.16.12.3744.
N E Breslow, J B Beckwith, J Z Finklestein, P Grundy, P R Thomas, T Kim, S Shochat, G Haase, M Ritchey, P Kelalis, G J D'Angio
Affiliations
- PMID: 9850017
- DOI: 10.1200/JCO.1998.16.12.3744
Clinical Trial
Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group
D M Green et al. J Clin Oncol. 1998 Dec.
Abstract
Purpose: National Wilms' Tumor Study (NWTS)-4 was designed to evaluate the efficacy, toxicity, and cost of the administration of different regimens for the treatment of Wilms' tumor (WT).
Patients and methods: Between August 6, 1986 and September 1, 1994, 905 previously untreated children aged younger than 16 years with stage II favorable histology (FH) WT (low-risk [LR]), stages III to IV FH WT, or stages I to IV clear-cell sarcoma of the kidney (high-risk[HR]) were randomized after the completion of 6 months of chemotherapy to discontinue (short) or continue for 9 additional months (long) treatment with chemotherapy regimens that included vincristine and either divided-dose (standard [STD]) courses (5 days) or single-dose (pulse-intensive [PI]) treatment with dactinomycin. HR patients also received either divided-dose (STD) courses (3 days) or single-dose (PI) treatment with doxorubicin.
Results: The 4-year relapse-free survival (RFS) rates after the second randomization for LR patients were 83.7% for the 190 patients treated with short and 88.2% for the 187 patients treated with long chemotherapy (P = .11). The 4-year RFS rates after the second randomization for HR FH patients were 89.7% for the 256 patients treated with short and 88.8% for the 246 patients treated with long chemotherapy (P = .87). The charge for treatment with the short PI treatment regimens for all children with stages I through IV FH WT was approximately one half of that with the long STD treatment regimens.
Conclusion: The short administration schedule for the treatment of children with WT is no less effective than the long administration schedule and can be administered at a substantially lower total treatment cost.
Similar articles
-
Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy PE, Thomas PR, Kim T, Shochat SJ, Haase GM, Ritchey ML, Kelalis PP, D'Angio GJ. Green DM, et al. J Clin Oncol. 1998 Jan;16(1):237-45. doi: 10.1200/JCO.1998.16.1.237. J Clin Oncol. 1998. PMID: 9440748 Clinical Trial.
-
Seibel NL, Li S, Breslow NE, Beckwith JB, Green DM, Haase GM, Ritchey ML, Thomas PR, Grundy PE, Finklestein JZ, Kim T, Shochat SJ, Kelalis PP, D'Angio GJ. Seibel NL, et al. J Clin Oncol. 2004 Feb 1;22(3):468-73. doi: 10.1200/JCO.2004.06.058. J Clin Oncol. 2004. PMID: 14752069 Clinical Trial.
-
Green DM, Breslow NE, Evans I, Moksness J, Finklestein JZ, Evans AE, D'Angio GJ. Green DM, et al. J Natl Cancer Inst Monogr. 1995;(19):21-5. J Natl Cancer Inst Monogr. 1995. PMID: 7577200 Clinical Trial.
-
Treatment of Wilms' tumour. Current recommendations.
Mehta MP, Bastin KT, Wiersma SR. Mehta MP, et al. Drugs. 1991 Nov;42(5):766-80. doi: 10.2165/00003495-199142050-00004. Drugs. 1991. PMID: 1723373 Review.
-
Adult Wilms' tumor. Report of two cases and review of the literature.
Hentrich MU, Meister P, Brack NG, Lutz LL, Hartenstein RC. Hentrich MU, et al. Cancer. 1995 Jan 15;75(2):545-51. doi: 10.1002/1097-0142(19950115)75:2<545::aid-cncr2820750218>3.0.co;2-c. Cancer. 1995. PMID: 7812923 Review.
Cited by
-
Kim HY, Veal GJ, Zhou F, Boddy AV. Kim HY, et al. Eur J Clin Pharmacol. 2018 Dec;74(12):1575-1584. doi: 10.1007/s00228-018-2544-z. Epub 2018 Aug 30. Eur J Clin Pharmacol. 2018. PMID: 30167756
-
Current and emerging chemotherapy treatment strategies for Wilms tumor in North America.
Gratias EJ, Dome JS. Gratias EJ, et al. Paediatr Drugs. 2008;10(2):115-24. doi: 10.2165/00148581-200810020-00006. Paediatr Drugs. 2008. PMID: 18345721 Review.
-
Oosterom N, Gooskens SLM, Renfro LA, Perlman EJ, van den Heuvel-Eibrink MM, Hamilton TE, Green DM, Grundy PE, Daw NC, Geller JI, Dome JS, Fernandez CV, Mullen EA. Oosterom N, et al. J Clin Oncol. 2023 Sep 10;41(26):4247-4256. doi: 10.1200/JCO.22.02555. Epub 2023 Jun 21. J Clin Oncol. 2023. PMID: 37343199 Free PMC article.
-
Pediatric genitourinary tumors: Distribution, demographics, and outcomes.
Nazemi A, Daneshmand S, Chang A. Nazemi A, et al. Pediatr Investig. 2022 Mar 31;6(2):85-92. doi: 10.1002/ped4.12318. eCollection 2022 Jun. Pediatr Investig. 2022. PMID: 35774527 Free PMC article.
-
Fernandez CV, Mullen EA, Chi YY, Ehrlich PF, Perlman EJ, Kalapurakal JA, Khanna G, Paulino AC, Hamilton TE, Gow KW, Tochner Z, Hoffer FA, Withycombe JS, Shamberger RC, Kim Y, Geller JI, Anderson JR, Grundy PE, Dome JS. Fernandez CV, et al. J Clin Oncol. 2018 Jan 20;36(3):254-261. doi: 10.1200/JCO.2017.73.7999. Epub 2017 Dec 6. J Clin Oncol. 2018. PMID: 29211618 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous